Illumina Fights EU to Convey $7 Billion Grail Bid Again From Brink

Illumina Inc.’s battle to avoid wasting its $7 billion acquisition of cancer-test supplier Grail Inc. enters the ultimate levels on Tuesday in a courtroom problem to the European Union’s energy to probe offers that when flew underneath the radar.

A listening to on the EU’s Court docket of Justice is Illumina’s final probability to persuade judges that the European Fee over-reached by blocking a mixture that lacked any discernible footprint within the 27-nation EU. A closing ruling is anticipated within the coming months.